These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23568616)

  • 1. New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients.
    Pilcer G; Rosière R; Traina K; Sebti T; Vanderbist F; Amighi K
    J Pharm Sci; 2013 Jun; 102(6):1836-1846. PubMed ID: 23568616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis.
    Pilcer G; De Bueger V; Traina K; Traore H; Sebti T; Vanderbist F; Amighi K
    Int J Pharm; 2013 Jul; 451(1-2):112-20. PubMed ID: 23643509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs.
    Miller DP; Tan T; Tarara TE; Nakamura J; Malcolmson RJ; Weers JG
    Mol Pharm; 2015 Aug; 12(8):2582-93. PubMed ID: 26052676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery.
    Pilcer G; Vanderbist F; Amighi K
    Int J Pharm; 2009 Jan; 365(1-2):162-9. PubMed ID: 18782609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties.
    Pilcer G; Vanderbist F; Amighi K
    J Pharm Sci; 2009 Apr; 98(4):1463-75. PubMed ID: 18752304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
    Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
    Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel combination proliposomes containing tobramycin and clarithromycin effective against Pseudomonas aeruginosa biofilms.
    Ye T; Sun S; Sugianto TD; Tang P; Parumasivam T; Chang YK; Astudillo A; Wang S; Chan HK
    Int J Pharm; 2018 Dec; 552(1-2):130-138. PubMed ID: 30267753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
    Li X; Vogt FG; Hayes D; Mansour HM
    J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nano into Micro Formulations of Tobramycin for the Treatment of Pseudomonas aeruginosa Infections in Cystic Fibrosis.
    Porsio B; Cusimano MG; Schillaci D; Craparo EF; Giammona G; Cavallaro G
    Biomacromolecules; 2017 Dec; 18(12):3924-3935. PubMed ID: 29111673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™ family.
    Hoppentocht M; Akkerman OW; Hagedoorn P; Frijlink HW; de Boer AH
    Eur J Pharm Biopharm; 2015 Feb; 90():8-15. PubMed ID: 25615881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation.
    Pilcer G; Sebti T; Amighi K
    Pharm Res; 2006 May; 23(5):931-40. PubMed ID: 16715383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility.
    Manniello MD; Del Gaudio P; Aquino RP; Russo P
    Int J Pharm; 2017 Nov; 533(2):463-469. PubMed ID: 28377314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency.
    Parlati C; Colombo P; Buttini F; Young PM; Adi H; Ammit AJ; Traini D
    Pharm Res; 2009 May; 26(5):1084-92. PubMed ID: 19184617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward Repositioning Niclosamide for Antivirulence Therapy of Pseudomonas aeruginosa Lung Infections: Development of Inhalable Formulations through Nanosuspension Technology.
    Costabile G; d'Angelo I; Rampioni G; Bondì R; Pompili B; Ascenzioni F; Mitidieri E; d'Emmanuele di Villa Bianca R; Sorrentino R; Miro A; Quaglia F; Imperi F; Leoni L; Ungaro F
    Mol Pharm; 2015 Aug; 12(8):2604-17. PubMed ID: 25974285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerodynamic properties, solubility and in vitro antibacterial efficacy of dry powders prepared by spray drying: Clarithromycin versus its hydrochloride salt.
    Manniello MD; Del Gaudio P; Porta A; Aquino RP; Russo P
    Eur J Pharm Biopharm; 2016 Jul; 104():1-6. PubMed ID: 27106605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.
    Geller DE; Weers J; Heuerding S
    J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):175-82. PubMed ID: 21395432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
    Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J
    Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
    Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.